Logo image of EVOK

EVOKE PHARMA INC (EVOK) Stock Fundamental Analysis

NASDAQ:EVOK - Nasdaq - US30049G3020 - Common Stock - Currency: USD

3.22  +0.05 (+1.42%)

Fundamental Rating

3

Taking everything into account, EVOK scores 3 out of 10 in our fundamental rating. EVOK was compared to 198 industry peers in the Pharmaceuticals industry. EVOK has a bad profitability rating. Also its financial health evaluation is rather negative. EVOK is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year EVOK has reported negative net income.
In the past year EVOK has reported a negative cash flow from operations.
In the past 5 years EVOK always reported negative net income.
In the past 5 years EVOK always reported negative operating cash flow.
EVOK Yearly Net Income VS EBIT VS OCF VS FCFEVOK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2M -4M -6M -8M -10M

1.2 Ratios

EVOK has a Return On Assets (-30.55%) which is in line with its industry peers.
EVOK has a Return On Equity (-76.05%) which is in line with its industry peers.
Industry RankSector Rank
ROA -30.55%
ROE -76.05%
ROIC N/A
ROA(3y)-70.05%
ROA(5y)-86.08%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
EVOK Yearly ROA, ROE, ROICEVOK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400 -400

1.3 Margins

Looking at the Gross Margin, with a value of 96.52%, EVOK belongs to the top of the industry, outperforming 96.97% of the companies in the same industry.
In the last couple of years the Gross Margin of EVOK has grown nicely.
The Profit Margin and Operating Margin are not available for EVOK so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 96.52%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.62%
GM growth 5YN/A
EVOK Yearly Profit, Operating, Gross MarginsEVOK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20K -40K -60K

More info and screens

2

2. Health

2.1 Basic Checks

EVOK has more shares outstanding than it did 1 year ago.
The number of shares outstanding for EVOK has been reduced compared to 5 years ago.
Compared to 1 year ago, EVOK has an improved debt to assets ratio.
EVOK Yearly Shares OutstandingEVOK Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M
EVOK Yearly Total Debt VS Total AssetsEVOK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

2.2 Solvency

EVOK has an Altman-Z score of -9.95. This is a bad value and indicates that EVOK is not financially healthy and even has some risk of bankruptcy.
EVOK's Altman-Z score of -9.95 is on the low side compared to the rest of the industry. EVOK is outperformed by 71.72% of its industry peers.
A Debt/Equity ratio of 0.71 indicates that EVOK is somewhat dependend on debt financing.
EVOK has a worse Debt to Equity ratio (0.71) than 66.67% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.71
Debt/FCF N/A
Altman-Z -9.95
ROIC/WACCN/A
WACCN/A
EVOK Yearly LT Debt VS Equity VS FCFEVOK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M -10M

2.3 Liquidity

EVOK has a Current Ratio of 1.66. This is a normal value and indicates that EVOK is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.66, EVOK is doing worse than 68.18% of the companies in the same industry.
A Quick Ratio of 1.62 indicates that EVOK should not have too much problems paying its short term obligations.
EVOK has a worse Quick ratio (1.62) than 61.62% of its industry peers.
Industry RankSector Rank
Current Ratio 1.66
Quick Ratio 1.62
EVOK Yearly Current Assets VS Current LiabilitesEVOK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

7

3. Growth

3.1 Past

EVOK shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 83.76%, which is quite impressive.
Looking at the last year, EVOK shows a very strong growth in Revenue. The Revenue has grown by 98.02%.
The Revenue has been growing by 84.95% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)83.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%91.1%
Revenue 1Y (TTM)98.02%
Revenue growth 3Y84.95%
Revenue growth 5YN/A
Sales Q2Q%97.44%

3.2 Future

EVOK is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 33.34% yearly.
Based on estimates for the next years, EVOK will show a very strong growth in Revenue. The Revenue will grow by 52.59% on average per year.
EPS Next Y81.8%
EPS Next 2Y47.26%
EPS Next 3Y33.34%
EPS Next 5YN/A
Revenue Next Year59.23%
Revenue Next 2Y58.67%
Revenue Next 3Y52.59%
Revenue Next 5YN/A

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
EVOK Yearly Revenue VS EstimatesEVOK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 10M 20M 30M
EVOK Yearly EPS VS EstimatesEVOK Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -100 -200 -300

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for EVOK. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for EVOK. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EVOK Price Earnings VS Forward Price EarningsEVOK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EVOK Per share dataEVOK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6

4.3 Compensation for Growth

EVOK's earnings are expected to grow with 33.34% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y47.26%
EPS Next 3Y33.34%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for EVOK!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EVOKE PHARMA INC

NASDAQ:EVOK (5/16/2025, 4:30:01 PM)

3.22

+0.05 (+1.42%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-13 2025-03-13/amc
Earnings (Next)05-20 2025-05-20
Inst Owners14.7%
Inst Owner Change0%
Ins Owners4.43%
Ins Owner Change0.59%
Market Cap4.80M
Analysts82.86
Price Target18.36 (470.19%)
Short Float %1.75%
Short Ratio1.1
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-70.28%
Min EPS beat(2)-142.52%
Max EPS beat(2)1.96%
EPS beat(4)2
Avg EPS beat(4)-36.64%
Min EPS beat(4)-142.52%
Max EPS beat(4)20.63%
EPS beat(8)4
Avg EPS beat(8)-16.42%
EPS beat(12)6
Avg EPS beat(12)-17.17%
EPS beat(16)9
Avg EPS beat(16)-10.63%
Revenue beat(2)1
Avg Revenue beat(2)-8.66%
Min Revenue beat(2)-22.51%
Max Revenue beat(2)5.18%
Revenue beat(4)1
Avg Revenue beat(4)-13.46%
Min Revenue beat(4)-22.51%
Max Revenue beat(4)5.18%
Revenue beat(8)4
Avg Revenue beat(8)-6.44%
Revenue beat(12)5
Avg Revenue beat(12)-5.52%
Revenue beat(16)7
Avg Revenue beat(16)0.53%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-268.75%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-20.19%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.47
P/FCF N/A
P/OCF N/A
P/B 0.68
P/tB 0.68
EV/EBITDA N/A
EPS(TTM)-4.54
EYN/A
EPS(NY)-0.83
Fwd EYN/A
FCF(TTM)-3.66
FCFYN/A
OCF(TTM)-3.66
OCFYN/A
SpS6.88
BVpS4.72
TBVpS4.72
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -30.55%
ROE -76.05%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 96.52%
FCFM N/A
ROA(3y)-70.05%
ROA(5y)-86.08%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.62%
GM growth 5YN/A
F-Score3
Asset Turnover0.59
Health
Industry RankSector Rank
Debt/Equity 0.71
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.66
Quick Ratio 1.62
Altman-Z -9.95
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)83.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%91.1%
EPS Next Y81.8%
EPS Next 2Y47.26%
EPS Next 3Y33.34%
EPS Next 5YN/A
Revenue 1Y (TTM)98.02%
Revenue growth 3Y84.95%
Revenue growth 5YN/A
Sales Q2Q%97.44%
Revenue Next Year59.23%
Revenue Next 2Y58.67%
Revenue Next 3Y52.59%
Revenue Next 5YN/A
EBIT growth 1Y29.94%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-9.5%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-9.5%
OCF growth 3YN/A
OCF growth 5YN/A